Head-to-head · WeighScore
NovoCare Pharmacy vs Vea Health
The verdict
NovoCare Pharmacy takes it — 55.2/100 to 55/100, but only just.
NovoCare Pharmacy grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Novo Nordisk's first-party direct-to-consumer pharmacy for branded Wegovy (semaglutide). Vea Health is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | NovoCare Pharmacy | Vea Health |
|---|---|---|
| WeighScore | 55.2/100 | 55/100 |
| Grade | C | C |
| Scorecard rank | #442 | #450 |
| Semaglutide | $349/mo (2.4 mg dose, brand-name) | Not disclosed |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Yes |
Graded #442 · C
Strengths
- First-party Novo Nordisk pharmacy — the most authoritative branded Wegovy channel
- $199/mo intro pricing on Wegovy 0.25/0.5 mg starter doses (through 6/30/2026), the lowest brand self-pay price
- $349/mo standard self-pay is well below the ~$1,300/mo retail list price
- Ships to all 50 states with no telehealth-platform middleman fees
- Cold-chain logistics handled directly by Novo Nordisk
Where it loses points
- Wegovy only — no Ozempic, no tirzepatide, no compounded GLP-1
- Requires an existing Wegovy prescription — no prescribing clinicians or telehealth intake
- No clinical support included — your own prescriber handles titration and side effects
- Manufacturer-set pricing can change at any time
- $199 pen intro covers only the first 2 fills for new patients (through 6/30/2026); maintenance doses are $349/mo ($399 HD)
Graded #450 · C
Strengths
- Publishes the FDA compounded-medication disclaimer
- Oral and injection protocols for both semaglutide and tirzepatide
- Claims 50-state coverage via a clinician network
- Clearly differentiated positioning (longevity, men's health, performance)
Where it loses points
- Pricing not shown until after sign-up
- Pharmacy partner not named (only 'U.S.-based pharmacy')
- LegitScript certification status not visible
- No named medical director
- 503A vs 503B designation not specified
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.